Eric Drape - 05 Mar 2024 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role
Executive VP Global Operations
Signature
/s/ Dov Bergwerk as attorney-in-fact for Eric Drape
Issuer symbol
TEVA
Transactions as of
05 Mar 2024
Net transactions value
$0
Form type
4
Filing time
07 Mar 2024, 16:24:19 UTC
Previous filing
05 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TEVA Ordinary Shares Options Exercise +22,576 +33% 90,689 05 Mar 2024 Direct F1, F2, F3
transaction TEVA Ordinary Shares Options Exercise +55,226 +61% 145,915 05 Mar 2024 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TEVA Restricted Share Units Options Exercise $0 -22,576 -50% $0.000000 22,576 05 Mar 2024 Ordinary Shares 22,576 Direct F2, F4
transaction TEVA Restricted Share Units Options Exercise $0 -55,226 -100% $0.000000* 0 05 Mar 2024 Ordinary Shares 55,226 Direct F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3 Amount reflects the sale of 9,815 Ordinary Shares by the Reporting Person, as reported in a Form 4 filed on March 1, 2024, which was inadvertently omitted from the amount of securities beneficially owned by the Reporting Person following the transactions reported in a Form 4 filed on March 5, 2024.
F4 Restricted share units were granted on March 5, 2021, with 22,576 vested on March 5, 2022, March 5, 2023, March 5, 2024 and 22,576 vesting on March 5, 2025.
F5 Restricted share units were granted on January 30, 2024 pursuant to the satisfaction of performance criteria and vested on March 5, 2024.